Related Experiment Video

Updated: Jan 19, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

13.8K

Relationship between monocyte to HDL cholesterol ratio and concomitant cardiovascular disease in Chinese Han patients

Ning Li1,2, Lei Ren3, Jia Hui Wang1,2

  • 1Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Cardiovascular Diagnosis and Therapy
|September 27, 2019
PubMed

Insights

Monocyte to HDL cholesterol ratio (MHR) is linked to obstructive sleep apnea (OSA) severity and cardiovascular disease (CVD) in Chinese patients. MHR shows promise as a biomarker for predicting CVD in OSA.

Area of Science:

  • Cardiology
  • Sleep Medicine
  • Biomarkers

Background:

  • Obstructive sleep apnea (OSA) is a significant risk factor for cardiovascular disease (CVD), primarily driven by inflammation from chronic intermittent hypoxia (CIH).
  • The monocyte to high-density lipoprotein cholesterol ratio (MHR) is an emerging inflammatory biomarker for CVD, yet its role in OSA remains understudied.
  • This study investigates the association between MHR and CVD in Chinese Han patients diagnosed with OSA.

Purpose of the Study:

  • To explore the correlation between MHR and the presence of CVD in Chinese Han patients with OSA.
  • To assess MHR as a potential predictor of CVD in the context of OSA severity.

Main Methods:

  • A cross-sectional study involving 657 Chinese Han subjects, including controls and patients with mild, moderate, and severe OSA.
  • Analysis of the relationship between MHR levels and concomitant CVD in OSA patients.
  • Statistical methods included logistic regression and ROC analysis to evaluate MHR's predictive value.

Main Results:

  • MHR levels positively correlated with apnea-hypopnea index (AHI) and negatively with lowest SpO2.
  • OSA patients with CVD exhibited significantly higher MHR values compared to those without CVD.
  • MHR was identified as an independent predictor of CVD in OSA patients, with specific cut-off values determined for prediction.

Conclusions:

  • MHR is strongly associated with both OSA severity and the occurrence of CVD in OSA patients.
  • MHR is a readily available and promising biomarker for predicting CVD in Chinese Han patients suffering from OSA.
Abstract

Keywords:
Obstructive sleep apnea (OSA)biomarkercardiovascular disease (CVD)monocyte to high-density lipoprotein cholesterol ratio (MHR)

More Related Videos

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders05:34

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

3.3K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.4K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
591
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
484
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
893
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
263